Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
BISPECIFIC NANO-ANTIBODY USED FOR TREATING CEA POSITIVE EXPRESSION TUMOUR
Document Type and Number:
WIPO Patent Application WO/2017/025033
Kind Code:
A1
Abstract:
A bispecific nano-antibody, including: (a) a first binding domain having specific binding with human CEA, the first binding domain including an anti-human CEA VHH, and (b) a second binding domain having specific binding with human CD16, the second binding domain including an anti-human CD16 VHH. The antibody molecule is capable of soluble expression within a prokaryotic expression system, is beneficial for subsequent separation and purification, has relatively good heat stability, and is highly soluble. In addition, the antibody fragments used in the present invention come from camelid heavy-chain antibody variable region sequences, have high binding affinity with antigens, have a relatively high homology with human immunoglobulin heavy-chain variable region sequences, and have weak antigenicity.

Inventors:
WANG ZHONG (CN)
LI QING (CN)
Application Number:
PCT/CN2016/094365
Publication Date:
February 16, 2017
Filing Date:
August 10, 2016
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV SUN YAT SEN (CN)
International Classes:
A61K39/395; C07K16/46; A61P35/00; C07K16/28; C07K16/30; C12N15/13
Domestic Patent References:
WO2005061547A22005-07-07
Foreign References:
CN102482701A2012-05-30
Other References:
G.BEHAR ET AL.: "Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen.", THE FEBS JOURNAL, vol. 276, no. 14, 15 June 2009 (2009-06-15), XP002646407
Attorney, Agent or Firm:
WINGUAN PATENT AND TRADEMARK ATTORNEYS (CN)
Download PDF: